Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on September 13, 2018. The report details corporate governance changes, specifically the retirement of a director and the appointment of a new director, as well as an amendment to the company's Restated Certificate of Incorporation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate actions rather than financial performance results.
Material Changes
- Board Composition: Mr. Russell Harrison retired from the Board effective September 19, 2018, after serving since February 2014.
- New Appointment: Mr. Philippe Weigerstorfer was appointed as an independent director effective September 19, 2018, replacing Mr. Harrison. He was also appointed to the Audit Committee and the Nominating and Corporate Governance Committees.
- Compensation and Equity: Mr. Weigerstorfer will receive an annual retainer of $32,500, plus $7,500 for each committee membership. He was granted 22,500 shares of common stock vesting over three years.
- Authorized Capital: The company increased its authorized common stock from the previous amount to 24,000,000 shares, effective September 13, 2018.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding intentions, beliefs, and expectations. Management notes that actual outcomes may differ materially due to risks and uncertainties discussed in the company's Form 10-K. No specific financial guidance or operational outlook was provided in this document.
Investor Verification Checklist
- Verify the effective date of the new director's appointment and the retirement of the former director (September 19, 2018).
- Confirm the total number of authorized shares is now 24,000,000.
- Review the specific vesting schedule for the 22,500 shares granted to the new director.
- Check the company's most recent Form 10-K for detailed financial performance and risk factors not included in this 8-K.